Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients.

about

Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients.

Item

http://www.wikidata.org/entity/Q38633201

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Early skeletal muscle loss dur ...... renal cell carcinoma patients.

@en

type

Item

label

Early skeletal muscle loss dur ...... renal cell carcinoma patients.

@en

prefLabel

Early skeletal muscle loss dur ...... renal cell carcinoma patients.

@en

P1476

Early skeletal muscle loss dur ...... renal cell carcinoma patients

@en

P2093

Dingwei Ye

http://www.w3.org/2001/XMLSchema#string

Guohai Shi

http://www.w3.org/2001/XMLSchema#string

Hailiang Zhang

http://www.w3.org/2001/XMLSchema#string

Junlong Wu

http://www.w3.org/2001/XMLSchema#string

Weijie Gu

http://www.w3.org/2001/XMLSchema#string

Xiaohang Liu

http://www.w3.org/2001/XMLSchema#string

P2860

NIH ImageJ and Slice-O-Matic computed tomography imaging software to quantify soft tissue

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

Definition and classification of cancer cachexia: an international consensus.

Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis.

Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma.

Prognostic value of components of body composition in patients treated with targeted therapy for advanced renal cell carcinoma: a retrospective case series

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients.

Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer.

Prognostic Significance of Sarcopenia in Patients with Metastatic Renal Cell Carcinoma.

P2888

s41598-017-07955-6

P304

7587

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-07955-6

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yao Zhu

P577

2017-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091025351

http://www.w3.org/2001/XMLSchema#string

P698

28790354

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

P932

5548774

http://www.w3.org/2001/XMLSchema#string